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Background/aim: During the COVID-19 pandemic, the risk of transmission of SARS-CoV-2 has not been precisely known in bronchoscopy
procedures. We have designed a cabinet device called Ankara University Bronchoscopy Cabinet (Aubrocab®) to protect healthcare. We
aimed to evaluate preventing effect of Aubrocab® on aerosol spreading by measuring the particles in the bronchoscopy suite.
Materials and methods: The patients were categorized into two groups as those who underwent bronchoscopy with and without Aubrocab®.
We measured PM 0.5 levels before and after bronchoscopy in the bronchoscopy suite.
Results: A total of 82 patients, 62 of whom underwent bronchoscopy with Aubrocab®, were enrolled in the study. The PM 0.5 level measured
before bronchoscopy was similar in both groups, whereas the PM 0.5 level measured after bronchoscopy was lower in the Aubrocab® group
(42,603 ± 8,632 vs. 50,377 ± 10,487, p = 0.001). The percent of particle change (50.76 ± 19.91 vs 67.15 ± 24.24, p = 0.003) and the difference
of the particle numbers between pre and postprocedure (13,638 ± 4,292 and 19,501 ± 5,891, p < 0.001) were lower in the Aubrocab® group.
Conclusion: Our institution developed a barrier device named Aubrocab® which was shown to prevent excessive aerosol release in addition
to routine precautions during bronchoscopy procedures.
Key words: Aerosol spread, bronchoscopy, COVID-19, viral transmission, bronchoscopy cabinet

1. Introduction
Although bronchoscopy is an important tool in both
diagnosing and treating lung diseases, the risk of viral spread
has raised concerns during the Coronavirus disease-2019
(COVID-19) pandemic. Various guidelines have been
published for bronchoscopy applications to reduce the
risk of infection transmission in the COVID-19 pandemic.
Although these guidelines have similarities and differences,
the main recommendations are based on wearing full
personal protective equipment, including face shields,
gowns, gloves, N-95 masks and respirators or powered airpurifying masks during a bronchoscopy procedure. It has
also been suggested that aerosol-generating procedures
such as bronchoscopy be applied in negative pressure
rooms [1-4]. On the other hand, a negative-pressure room
is not always available especially at the bedside or emergent
procedures owing to location facilities.
Within the current precautions on bronchoscopy
applications, the risk of transmission of severe acute

respiratory syndrome coronavirus 2 (SARS-CoV-2) and
other respiratory tract pathogens has not already been
precisely known. Concerns about the risk of transmission
have prompted researchers and clinicians to design new
protective devices such as rigid plastic barrier enclosures,
widely known as aerosol boxes [5–7]. Although in current
forms these devices are thought to be able to form a shield,
the effect on their involvement in aerosol spreading is
unclear.
Additionally, to our routine personal protective
procedures, we have designed a device called Ankara
University Bronchoscopy Cabinet (Aubrocab®-National
trademark registration approval has been obtained for
this name) to protect the healthcare team, patient, or
area of operation from droplets. Given that The Centers
for Disease Control and Prevention (CDC) indicated
airborne transmission via small droplets and particles
as an important route of virus spread in the pandemic1,
we aimed to evaluate preventing effect of Aubrocab® on

CDC (2020) Scientific Brief: SARS-CoV-2 and Potential Airborne Transmission [online]. Website https://www.cdc.gov/coronavirus/2019-ncov/science/
science-briefs/sars-cov-2-transmission.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fscience%2Fsciencebriefs%2Fscientific-brief-sars-cov-2.html (Accessed 19 May 2021),
1

* Correspondence: karnak@medicine.ankara.edu.tr

This work is licensed under a Creative Commons Attribution 4.0 International License.

361

GÜRÜN KAYA et al. / Turk J Med Sci
aerosol spreading by measuring the number of particles in
the bronchoscopy suite.
2. Materials and Methods
2.1. Study design
The prospective study was conducted in a bronchoscopy
unit of a university hospital to evaluate the efficacy and
safety of bronchoscopy with and without newly invented
bronchoscopy cabin Aubrocab®. In our preliminary
measurements by 6 bronchoscopies each (total 12) with or
without Aubrocab® we observed 41% and 77% of particle
increase in the bronchoscopy suite after the procedure,
respectively.
With the prediction that the rate of particle increases in
procedures with Aubrocab® will be significantly lower than
the procedures without it. The estimated required sample
size was a total of 80 patients, 60 with Aubrocab® and 20
without Aubrocab®, who were included in the study with
80% power at d = 0.50 effect size, α = 0.05 error level and
an allocation ratio of 3:1. The sample size for the study was
calculated using the GPower program (GPower Version
3.1.9.2). Patients were randomly assigned in a 3:1 ratio to
the procedure with or without Aubrocab®.
The study protocol was approved by the Ethics
Committee of the Ankara University School of Medicine
on 09 July 2020 (approval No. I7-400-20). Written
informed consent was obtained from each of the patients
before the procedure, and the study was conducted in
accordance with the amended Declaration of Helsinki.
2.2. Study patients
All patients were recruited from the bronchoscopy unit
of the university hospital from 01.08.2020 to 30.04.2021.
All bronchoscopy decisions were made by an experienced
pulmonologist. In line with our standard of the fiberoptic
bronchoscope (FB) procedure, all patients were evaluated by
clinical and laboratory findings. Absolute contraindications
for the FB procedure are: PaO2 < 60 mmHg after 100%
oxygen administration, presence of bronchospasm,
respiratory acidosis, cardiovascular system diseases
(recent myocardial infarction, stable-unstable angina,
arrhythmia, hypertension), presence of cerebrovascular
pathology, increased intracranial pressure, convulsion,
pneumothorax,
bleeding
diathesis
(international
normalised ratio (INR) ≥ 1.5), thrombocytopenia
(<50,000/mm3), thrombocyte dysfunction, severe anaemia
(Hb < 8g/dL), portal hypertension, and uremia. Patients
were also evaluated for possible signs of pulmonary
infection. The following patients were excluded from the
study: history of fever in the last 14 days, history of contact
with a person diagnosed with COVID-19 within 14 days,
subjects with newly developed cough, sputum, shortness
of breath, diarrhea findings within 14 days and patients
whose radiologically findings suggestive of viral infection.
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Patients with these findings were referred to relevant
clinics to be investigated for possible infection conditions,
and bronchoscopy procedures were postponed. Within 24
h before the bronchoscopy procedure, the SARS-CoV-2
reverse transcriptase-polymerase chain reaction (rt-PCR)
test was performed, when the test was negative.
2.3. Bronchoscopy procedure
Conventional procedures were performed in the supine
position via the transoral route by trained bronchoscopists
(DK, AÇ, AGK, MÖ, SE, AK) using a flexible bronchoscope
(FB) (Olympus Video bronchoscope BF1T200; Olympus,
Tokyo, Japan). Endobronchial ultrasound-guided
transbronchial needle aspiration(s) (EBUS-TBNAs)
were performed using a bronchoscope (BF-UC180F;
Olympus Medical, Japan) with an electronic convexarray ultrasound processor (EU-ME1; Olympus Medical,
Japan) to the distal tip. Bronchoscopy suite staff was not
more than four, all of whom had personal protective
equipment during the procedure. These procedures were
done under local anaesthesia with 2% lidocaine solution
for cough suppression with or without sedation with
midazolam (0.01–0.1 mg/kg) and/or fentanyl (25–100 μg).
Additionally, 2–4 mL of 2% lidocaine was administered
via a bronchoscope during the procedure at the vocal cord
level as a local anaesthetic for cough suppression.
2.4. Cabinet system (Aubrocab®)
A bronchoscopy cabinet with the name of Aubrocab®
has been designed for the healthcare team during the
bronchoscopy procedures in our clinic to reduce the risk
of transmission. Aubrocab® is a cabinet system consisting
of hygienic material such as plexiglass, stainless-steel and
rubber, with a smooth surface that prevents microorganisms
from adhering and can be easily washed. An antibacterial
transparent polyethylene cover is placed on the whole
surface of the Aubrocab®. This transparent cover creates a
barrier between the patient and the healthcare personnel
by covering both surface and apertures of the cabinet. Two
adapted polyethylene gloves, corresponding to the holes
on the surface of Aubrocab®, can be easily worn and taken
off by the bronchoscopist and assisting staff who holds the
mouthpiece and oxygen mask during the procedure. FB is
also covered by camera coverage beginning from the suction
canal to the upper half. The Aubrocab® is represented in
Figure 1: the front view during the procedure (Figure 1A),
the body of the cabinet, which is made of plexiglass and
stainless steel (Figure 1B), the transparent polyethylene
cover on the body and polyethylene gloves are worn by
the bronchoscopist and assisting staff (Figure 1C), right
side rear oblique view of the body of the cabinet and its
holes (Figure 1D), right side front oblique view (Figure
1E) and removal of polyethylene cover after the FB (Figure
1F). Also, the plan of Aubrocab® from a different view is
given in Figure 2. After each procedure, Aubrocab® is
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Figure 1. The front view of Aubrocab® during the procedure (A), the body of the cabinet, which is made of plexiglass and stainless steel
(B), the transparent polyethylene cover on the body and polyethylene gloves are worn by the bronchoscopist and assisting staff (C), right
side rear oblique view of the body of the cabinet and its holes (D), right side front oblique view (E) and removal of polyethylene cover
after the procedure (F).

disinfected as the following steps: 1) After waiting for five
min, polyethylene cover is folded inwards and destroyed
as medical waste; 2) the patient is removed from the cabin
by wearing a mask; 3) the surface of the cabinet is wiped
down for complete removal of mucus, blood, and visible
secretions via disposable towels inside the procedure
room; 4) the cabinet is mechanically washed cleaned
with a neutral detergent followed by decontamination of
surfaces using a high-level disinfectant. Staff should wear
PPE during all of the disinfection processes; 5) Terminal
decontamination of bronchoscopy suit using a mobile
automated UV light unit.
2.5. Particle measurements (PM)
The 42 square m area bronchoscopy suite where the study
was conducted is ventilated by a HEPA filter cleaning
PM over 0.5µm. The airborne particles measurements
were performed 5 m away from the door and near
the air conditioner by the same researcher at pre and

postprocedural time immediately via “Particles Plus®
8306 particle measurement device” that counts have
a detectable minimum particle diameter of 0.3 μm. In
this study, the concentrations of a PM recorded are the
cumulative data, and PM 0.5 are the concentrations of
particles ≤ 0.5μm. Such particles (<0.5 μm) may reach and
deposit in the alveoli where the air velocity is low and may
cause infection. This accumulation is directly proportional
to the procedure time [8]. The range of 2.5–10 µm,
including 0.5µm particles, are called coarse particles and
they are known to be very dispersive [9]. After measuring
the baseline and after procedure PMs, the percentage of
particle number change was calculated as follows: (postpre procedural number/preprocedural number) × 100 and
given as percent particle change.
2.6. Statistical analyses
The data was analysed using IBM SPSS Statistics (Version
22.0. Armonk, NY: IBM Corp.). Continuous variables
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Figure 2. The plan of the Aubrocab® from different views.

with normal distribution were presented as mean ±
standard deviation and as median [25th–75th percentiles,
interquartile range (IQR)] for nonnormal distributed
variables. A Kolmogorov-Smirnov test was used to analyse
the distribution of variables, and a Levene test was applied
to assess the equality of variances. An unpaired student’s
t-test or a Mann-Whitney U test were used to compare the
two groups. Categorical data were expressed as numbers
and percentages and compared with a chi-square test or
Fisher’s exact test, as appropriate. Repeated-measures
analysis of variance (ANOVA) model was used to analyse
the measurements taken from a homogeneous group of
patients at different time points. The statistical significance
level was expressed as p < 0.05 for all tests.
3. Results
Eighty-two patients enrolled in the study underwent
bronchoscopy. The mean age of the study group was
59.8 ± 12.8 years. Among the study patients, 53 (64.6%)
were male, and 62.2% of them had at least one comorbid
disease. In 82 bronchoscopy procedures, bronchial
washing samples (n = 42), bronchial biopsy (n = 21),
transbronchial needle aspiration (n = 40), bronchial
brushing (n = 8), bronchoalveolar lavage samples (n = 13),
and transbronchial biopsy (n = 3), were obtained.
While 60 procedures (73.2%) were performed under
moderate sedation using fentanyl and/or midazolam, 22
were performed under local anaesthesia. Forty (48.8%)
of 82 bronchoscopy procedures were performed with

364

endobronchial ultrasound (EBUS). While 62 (75.6%) of
bronchoscopies were performed with the Aubrocab® and
20 (37.8%) patients were performed without this system.
Basal demographic and clinical features of the groups that
underwent bronchoscopy with and without Aubrocab®
were similar (Table).
Airborne particle concentration level of PM 0.5
measured before bronchoscopy were similar in both
groups (28,965 ± 8,907 vs. 30,875 ± 8,470, p = 0.393),
whereas the PM 0.5 level measured just after bronchoscopy
was significantly lower in the Aubrocab® group compared
to the group without Aubrocab® (42,603 ± 8,632 vs. 50,377
± 10,487, p = 0.001) (Figure 3). The difference of the
particle numbers between pre and postprocedure were
also measured and compared in groups with or without
Aubrocab® 13.638 ± 4.292 and 19.501 ± 5.891 showing
statistical significance (p < 0.001) (Figure 4).
The percent particle changes between baseline and after
bronchoscopy measurements of particles were compared
between the groups. The analyses showed that the percent
particle change was significantly lower in the Aubrocab®
group (50,76 ± 19,91 vs. 67,15 ± 24,24, p = 0.003) (Figure
5).
All bronchoscopy procedures were well tolerated; no
hemodynamic instability occurred during the procedure,
and no patient required endotracheal intubation or
escalation for respiratory support. None of the patients
revealed symptoms suggestive of hypercapnia during
or after bronchoscopy. ANOVA model for repeated
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Table. Features of the patients included in the study.
With Aubrocab®
(n = 62)

Without Aubrocab®
(n = 20)

p

Age (years)

58.5 ± 12.8

63.9 ± 12.3

0.103

Gender (male)

41 (66.1%)

12 (60%)

0.618

Any comorbid disease

36 (58.1%)

15 (75%)

0.174

Chronic pulmonary disease

16 (25.8%)

6 (30%)

0.713

Hypertension

15 (24.2%)

7 (35%)

0.343

Diabetes mellitus

6 (9.7%)

5 (26.3%)

0.118

Coronary artery disease

5 (8.1%)

4 (20%)

0.211

Malignancy

11 (17.7%)

4 (20%)

0.999

Bronchoscopy

32 (51.6%)

10 (50%)

Bronchoscopy with EBUS

30 (48.4%)

10 (50%)

Local anaesthesia without sedation

19 (30.6%)

3 (15%)

Local anaesthesia with sedation

43 (69.4%)

17 (85%)

Duration of procedure (min)

19 (IQR25-75 17-26)

25.5 (IQR25-75 18-31)

0.999
0.170
0.113

60000

concentration, particles /m3

p= 0.001
55000

50000

45000

40000

with Aubrocab

without Aubrocab

Figure 3. Measured PM 0.5 levels of bronchoscopy room air at the postprocedural time with
and without Aubrocab® (p = 0.001). Y-axis represents the mean and 95% confidence interval
of particles count. The X-axis represents the two groups of patients.

measurements revealed no differences in the change in
oxygen saturation measured by pulse oximetry (SpO2) by
the time between procedures which were performed with
and without Aubrocab® (p = 0.702) (Figure 6). Although the
SpO2 value decreased compared to the baseline measured
value during the bronchoscopy procedures in both groups,
this decreasing trend was not clinically significant.
4. Discussion
This prospective study revealed that the use of Aubrocab®,
a bronchoscopy cabinet designed in our clinic, may be
an effective method to reduce aerosol dispersion during

the bronchoscopy procedure. During the COVID-19
pandemic, occupational exposure, and increased risk of
infection in healthcare workers remain a major concern
worldwide. To protect healthcare staff in the bronchoscopy
suite and patients and next coming patients undergoing
aerosol-generating procedures such as tracheal intubation
and bronchoscopy, various containment boxes, cabinets
or tents have been designed to act as a barrier against the
spread of aerosols [10–14]. However, there is no data about
the protective strength of the devices from aerosolised
pathogens [12]. To the best of our knowledge, this is the
first study to evaluate changing particle count during
Page 1
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p< 0.001

22500

20000

17500

15000

12500

with Aubrocab

without Aubrocab

Figure 4. Pre and postprocedural particle difference in number with and without Aubrocab®
(p < 0.001). Y-axis represents the mean and 95% confidence interval of the difference between
pre and postprocedural particles in number. The X-axis represents the two groups of patients.

80

percentage of particle difference (%)

p= 0.003
70

60

50

Page 1

40

with Aubrocab

without Aubrocab

Figure 5. Pre and postprocedural particle change in percentage with and without Aubrocab®
(p = 0.003). Y-axis represents the mean and 95% confidence interval of percentages of
particles change. The X-axis represents the two groups of patients.

the procedure in a bronchoscopy suite without negative
pressure.
Canelli et al. reported a simulation study that exploded
a small latex balloon containing fluorescent dye placed in
the hypopharynx of a human-like model. The explosion
of the balloon represented a crude depiction of a cough,
and the authors repeated the experiment with and without
the aerosol box to illuminate the scene with ultraviolet
light to visualise the spreading of the dye in each situation.
Their simulation suggested that the box helps restrict
the spread of droplets and may a barrier enclosure
provide a modicum of additional protection and could
be considered an adjunct to standard personal protective
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equipment [7]. Similarly, Kloka and colleagues conducted
another model simulation study in which the fluorescent
dye represented droplets and aerosols with another device
named COVid aErosol pRotEction Dome - COVERED.
The authors suggested the protective effect of COVERED
against coughing during intubation evaluated of visible
with fluorescent dye [15]. Recker and Gross described a
protective bronchoscopy tent. The authors reported that
they did not detect any droplet leakage during simulated
aerosol generation using a standard nebuliser with
backlighting to highlight particles [11]. Both studies
showed that with a fluorescent dye, the dye particles
representing the droplets are large enough to be visualised
Page 1
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96.00

with Aubrocab
without Aubrocab
95.50

SpO2%

p= 0.702
95.00

94.50

94.00

93.50

0. min

10. min

at the end of the
procedure

Figure 6. A repeated-measures ANOVA revealed no significant difference in treatment
between procedures performed with and without Aubrocab® (p = 0.702). Y-axis represents
the SpO2 level ( % ). The X-axis represents the time.

and can be delineated of large droplets. However, the
visible fluorescent dye could not simulate the small size
aerosols that could reach into the lung parenchyma via
inhalation. Doggett et al. noted an increase in fine particles
during elective bronchoscopy procedure, whereas noted
a reduction of larger particle generation. The authors
attributed this reduction of larger particles to obstructions
such as the inserted bronchoscope and gauze used around
the scope and bite block, which may affect releasing larger
particles during procedures [16].
In the present study, we evaluated the effectivity of the
Aubrocab®, via measuring a small particle size of less than
0.5 μm may diffuse and accumulate in the alveoli because
of smaller airway structures and longer residence time
[17,18]. Our findings suggested that the use of Aubrocab®
can decrease the small aerosol particles spread during
bronchoscopy. However, it should be noted that the
number of particles does not reflect the actual quantity
of the virus-containing particles. Previous studies showed
viral infections agents could be carried by aerosols,
especially in the range of very small size, and measurement
of those can be used to simulate viral spread [19]. Guzman
conducted a study to evaluate the effect of bioaerosol size
in SARS-CoV-2 transmission and reported maximum
concentrations of viral RNA with 40 copies per cubic m in
particles with sizes from 0.25 to 0.5 μm [20]. Similarly, in
another study, peak concentrations of SARS-CoV-2 RNA
40 and 9 copies/m3 in the aerosol with sizes of 0.25–0.5 μm
and 0.5–1.0 μm, respectively were detected [21]. Lednicky
et al. observed viable SARS-CoV-2 RNA in the collection
of airborne particles of the size range of 0.25 to 0.5 µm from
the air of a car being driven by a person with COVID-19
[22]. Previously Hersen and colleagues reported that
patients with respiratory system infectious, particularly

influenza and corona infections produce many aerosols,
especially in the range of small size with less than 1 µm
[23]. Many other studies revealed a significant amount of
influenza virus in the aerosol with small size [24–26].
Although Aubrocab® has similarities with previously
designed devices for barrier enclosure to aerosol [6,
12, 13, 15]; probably had more advantages in that it is
ergonomically designed with its curve shape that provides
bronchoscopist can stand closer to the patient and allows
for comfortable movement of the hands. Also, the device
provides patient visibility and communication with
its colourless and transparent structure. Polyethylene
cover that placed the whole surface and polyethylene
gloves positioned to Page
an1 aperture through which the
bronchoscopists’ hands are passed act a shield against
aerosol spreading. Aubrocab® is also more practical and
economical than devices with negative pressure or smoke
evacuation attachments [27, 28].
We did not observe any major complications requiring
early termination of the procedure, endotracheal
intubation, hemodynamic instability, or escalation in
the respiratory support in patients who underwent a
bronchoscopy with or without Aubrocab®. No significant
decrease in oxygen saturation was detected in the patients
monitored during the procedure. In addition, there was
no hypercapnia symptom that may be associated with
hypoventilation or rebreathing that might occur during
the procedure [29]. We suggest that the appropriate patient
evaluation before the procedure is the key factor to reduce
complication risk for all bronchoscopy procedures. Such
closed systems like Aubrocab® may trigger claustrophobia,
and anxiety [12], however, we did not observe any.
We believe that good communication and appropriate
sedation are essential for success.
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One of the limitations of our study is that it is carried
out at a single medical institution. Besides, conditions
such as coughing and sneezing, which increase the aerosol
formation have not been recorded, which may have
affected the particle measurements in the environment.
Moreover, we only measured the number of particles yet
we do not know whether these particles contain infected
material or not. Therefore, it may not be possible to reach
a clear conclusion by measuring the number of particles
in terms of viral transmission. In the preliminary phase of
the study, we measured significantly fewer particles in the
environment by using Aubrocab®. With this knowledge,
on further study, our colleagues refused to perform

bronchoscopy without Aubrocab® in order to increase the
control group. Therefore, we have a low number of the
control group.
In conclusion, our institution developed an ergonomic
and reusable barrier device named Aubrocab® which was
shown to prevent excessive aerosol release in addition
to routine precautions and standard personal protective
equipment during bronchoscopy procedures.
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